Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 15/20 | 0.59 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.56 |
| ▸ | AURKA | O14965 | 4/20 | 0.55 |
| ▸ | TNFRSF1A | P19438 | 4/20 | 0.55 |
| ▸ | SRC | P12931 | 3/20 | 0.55 |
| ▸ | PRKCB | P05771 | 1/20 | 0.55 |
| ▸ | STK3 | Q13188 | 1/20 | 0.55 |
| ▸ | MAP3K9 | P80192 | 3/20 | 0.54 |
| ▸ | KDR | P35968 | 2/20 | 0.54 |
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | LCK | P06239 | 2/20 | 0.48 |
| ▸ | CLK1 | P49759 | 2/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3586075 | 0.85 | MAP2K1 (0.83) | MAP2K1MAP2K2 | |
| SCHEMBL1563272 | 0.80 | AURKA (0.66) | MAP2K1MAP2K2AURKATNFRSF1ASRC | |
| SCHEMBL1563236 | 0.80 | MAP2K1 (0.65) | MAP2K1MAP2K2AURKATNFRSF1ASRC | |
| SCHEMBL1562455 | 0.79 | MAP2K1 (0.62) | MAP2K1 | |
| SCHEMBL1562726 | 0.78 | MAP2K1 (0.65) | MAP2K1MAP2K2AURKATNFRSF1ASRC | |
| SCHEMBL31130095 | 0.78 | MAP2K1 (0.65) | MAP2K1MAP2K2AURKATNFRSF1ASRC | |
| SCHEMBL34462118 | 0.78 | MAP2K1 (0.74) | MAP2K1MAP2K2AURKATNFRSF1ASRC | |
| SCHEMBL4860159 | 0.77 | MAP2K1 (0.75) | MAP2K1MAP2K2AURKATNFRSF1ASRC | |
| Trifluoroacetic Acid SCHEMBL1561955 | 0.76 | AURKA (0.60) | MAP2K1MAP2K2AURKATNFRSF1ASRC | |
| SCHEMBL1562380 | 0.74 | MAP2K1 (0.67) | MAP2K1MAP2K2AURKATNFRSF1ASRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575391-B2 | 5-substituted-2-phenylamino benzamides as MEK inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-11-05 | — | — | US | disclosed |
| US-8575391-B2 | 5-substituted-2-phenylamino benzamides as MEK inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-11-05 | — | — | US | disclosed |
| US-8575391-B2 | 5-substituted-2-phenylamino benzamides as MEK inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-11-05 | — | — | US | disclosed |
| EP-1780197-B9 | 5-SUBSTITUTED-2-PHENYLAMINO BENZAMIDES AS MEK INHIBITORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2011-04-06 | — | — | EP | disclosed |
| EP-1780197-B1 | 5-SUBSTITUTED-2-PHENYLAMINO BENZAMIDES AS MEK INHIBITORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-20100197676-A1 | 5-Substituted-2-Phenylamino Benzamides as Mek Inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197676-A1 | 5-Substituted-2-Phenylamino Benzamides as Mek Inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197676-A1 | 5-Substituted-2-Phenylamino Benzamides as Mek Inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-08-05 | — | — | US | disclosed |
| US-7745663-B2 | 5-Substituted-2-phenylamino benzamides as MEK inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-06-29 | — | — | US | disclosed |
| US-7745663-B2 | 5-Substituted-2-phenylamino benzamides as MEK inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20090233915-A1 | 5-Substituted-2-Phenylamino Benzamides as MEK Inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090233915-A1 | 5-Substituted-2-Phenylamino Benzamides as MEK Inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090233915-A1 | 5-Substituted-2-Phenylamino Benzamides as MEK Inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1780197-A1 | 5-SUBSTITUTED-2-PHENYLAMINO-BENZAMIDE AS MEK INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197676-A1 | 5-Substituted-2-Phenylamino Benzamides as Mek Inhibitors | BRAF, RAF1, NRAS | MAP2K1 41/4885MAP2K2 36/4885AURKA 461/4885 |
| US-20090233915-A1 | 5-Substituted-2-Phenylamino Benzamides as MEK Inhibitors | BRAF, RAF1, NRAS | MAP2K1 41/4885MAP2K2 36/4885AURKA 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.